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INTRODUCTION
Cytokines are small, soluble peptides or proteins that are 
produced by a variety of cells that participate in the immune 
response, including T cells, B cells, macrophages, mast cells, 
fibroblasts, and stromal cells, and are important immune 
mediators that constitute the communication network of the 
immune system. Cytokines regulate the responsiveness and 
maturation of particular cell populations, modulate the bal-
ance between cellular and humoral immune responses, and 
are important determinants of health and disease (O’Shea 
and Murray, 2008). The cytokine milieu provides impor-
tant insights into physiological and pathological processes 
and can potentially serve as biomarkers for various diseases 
(Paczesny et al., 2009; Suh and Kim, 2008). Therefore, deter-
mining the relative balance of cytokines is important in elu-
cidating the biological pathways that lead to inflammation, 
sepsis, and disease because dysregulation of these complex 
signaling pathways is often the earliest marker of a patholog-
ic response (Bozza et al., 2007; Chun et al., 2007).
In recent years, the Luminex assay has become an impor-
tant tool in cytokine detection and quantification because of 
its capacity to measure multiple different cytokines simulta-
neously in a single run of the assay with small sample size 
requirements. Thus, this technology enables patterns of 
numerous cytokines to be examined within and between 
experiments, which provides a more inclusive and compre-
hensive depiction of disease than measurement of individual 
cytokines—an approach that was not previously possible 
using conventional technologies such as ELISA (Tighe et al., 
2013).
GENERAL PRINCIPLES AND TECHNIQUE
Luminex assays enable fast and accurate measurements of 
cytokines by utilizing hundreds of specially prepared microm-
eter-scale plastic beads (referred to as microspheres), which 
are internally dyed with a graded mixture of red or infrared 
fluorescent dyes (Figure 1A). Varying the degree to which 
the beads are internally dyed creates hundreds of different 
fluorescent profiles that can be individually interrogated and 
classified in a single sample (Tighe et al., 2013).
Excitation of each of the unique microspheres by a laser, 
using modified flow cytometry–based instruments, causes 
them to emit light at different wavelengths. Microspheres of a 
single identity are conjugated on their surface with a specific 
capture antibody for a desired cytokine, which can be dif-
ferentiated from other microsphere sets by its unique spectral 
address (Figure 1B) (Dupont et al., 2005).
The biological sample of interest is then combined with a 
mixture of microsphere sets—each set specific for a unique 
cytokine—and incubated in a 96-well plate (Figure 1C). 
Using a variety of microsphere sets combined within a single 
assay, it is possible to carry out up to 100 tests in a single well 
of a 96-well plate. The biological sample–microsphere mix-
ture is then washed, and a cocktail of detection antibodies 
specific for the desired cytokines is added (Figure 1D). These 
detection antibodies are also conjugated with a reporter dye, 
which provides the microsphere with an additional distinct 
fluorescent emission signature when it binds the cytokine of 
interest (Tighe et al., 2013). Thus, it is possible to differenti-
ate various cytokines in a given sample based on the color of 
ADVANTAGES 
•  Multiplexing 100 tests in a single well of a 
96-well plate provides higher density and higher 
throughput in less time.
•  Requires significantly smaller sample volumes than 
traditional bioassays.
•  Results are as accurate as an ELISA and more 
reproducible than a microarray.
•  Customization of specific probes, including 
antibodies, receptors, peptides, and 
oligonucleotides, specific to a user’s needs.
LIMITATIONS
•  Requires dedicated analysis instruments, which 
creates high upfront installation costs.  
•  Analyses are subject to variability because of assay 
manufacturer, product lot number, and assay 
execution. 
•  The presence of human autoantibodies in some 
biological samples may confound the measurement 
of cytokines in clinical assays because of 
nonspecific binding. 
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the internally dyed beads themselves, while quantifying their 
relative abundance via measurement of the intensity of fluo-
rescence of the reporter dye–conjugated detection antibody.
After another round of washing, the microsphere–
cytokine–reporter compound is analyzed as a single-bead 
suspension through a flow chamber equipped with excita-
tion lasers and electronic detection apparatus that measures 
the intensity of fluorescence of the microsphere–cytokine–
reporter compound, similar to a flow cytometer (Figure 1E). 
Specifically, when a microsphere passes through the detec-
tion chamber, a red laser excites both the red and the infra-
red internal dyes inherent to each particular bead set, which 
allows the proper classification of the bead to 1 of the 100 
microsphere sets. A green laser then excites any reporter 
dye associated with the binding of the cytokine of interest. 
Notably, the amount of reporter bound to the microsphere is 
dependent on the concentration of the particular cytokine in 
the original biological sample (Figure 1F). The emitted light 
from the dyes is measured and used for quantitative analysis 
of each microsphere–cytokine–reporter conjugate. 
APPLICATIONS 
Luminex assays have revolutionized our ability to rapidly assess 
the relative concentration of various soluble factors that are 
important biological mediators of health and/or disease. Many 
rheumatologic, inflammatory, infectious, and genetic condi-
tions are modulated by the differential expression of anti- and 
proinflammatory cytokines, chemokines, and growth fac-
tors, and elucidation of these complex signaling pathways will 
likely augment our capacity for early diagnosis and drug dis-
covery. For example, Luminex profiling of epidermal explants 
from patients with systemic sclerosis was recently utilized to 
identify increased levels of profibrotic CCN2 (a connective 
tissue growth factor) and proinflammatory protein S100A9 
Figure 1. Luminex technique and general principles. (A) Plastic beads (100-μm scale) are internally dyed with a graded mixture of red and infrared fluorescent 
dyes, providing each microsphere with a unique fluorescent signature. (B) Microspheres of a single identity (i.e., the same fluorescent signature) are conjugated 
on their surface with a specific capture antibody for a desired cytokine. (C) A mixture of the 100 different microsphere sets is combined with the biological 
sample of interest in a 96-well plate, incubated, and then washed. (D) Next, a cocktail of detection antibodies conjugated with a reporter dye is added. Notably, 
a variety of detection antibodies are used, which are specific for different cytokines; however, the reporter dye is the same across all detection antibodies.  
(E) After another round of washing, the microspheres are analyzed as a single-bead suspension through a flow chamber similar to a flow cytometer. A red laser 
excites the internal red and infrared fluorescent dyes, which identifies and classifies the bead to one of the 100 microsphere sets. A green laser excites any bound 
detection antibody–reporter dye complex, and the intensity of this signal quantifies the relative amount of the cytokine bound to the microsphere.  
(F) Each microsphere traveling through the detection chamber thus has the following components: a capture antibody conjugated to its surface that is specific for 
a particular cytokine; a variable amount of a specific cytokine that is bound to the capture antibody, which is determined by the concentration of the cytokine in 
the original sample; and a detection antibody conjugated with a reporter dye that is also specific for the same particular cytokine.
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(Nikitorowicz-Buniak et al., 2014). These data suggest that the 
epidermis of these patients provides an important source of the 
profibrotic and proinflammatory factors that contribute to the 
fibrosis and inflammation seen in the disease, and CCN2 and 
S100A9 emerged as potential markers of disease severity and 
serve as possible targets for therapeutic intervention.
The use of Luminex assays for basic science discovery, pre-
clinical/translational studies, and clinical trial immune monitor-
ing has rapidly increased in recent years. In particular, Luminex 
assays have become widely utilized for biomarker analysis of 
small-volume samples. In solid-organ and vascularized com-
posite allotransplantation (such as hand and face transplanta-
tion), for example, Luminex assays have been utilized to predict 
high-risk antibodies, positive complement-dependent cytotox-
icity crossmatch, and immune monitoring of antibody-medi-
ated rejection and inflammatory cytokines (Campbell, 2013; 
Schneeberger et al., 2013).
Although the focus of this article is on the use of Luminex 
assays to quantify relative cytokine expression patterns, the pos-
sible applications of this technique extend far beyond cytokines. 
Indeed, it is possible to conjugate the surface of microspheres 
with antibodies, receptors, peptides, and oligonucleotides, 
thereby facilitating performance of immunoassays, receptor–
ligand assays, enzyme assays, and DNA assays, among oth-
ers, which meets the needs of a wide variety of applications 
Figure 2. The use of multiplex PCR and Luminex to screen for genomic variation in familial melanoma. Regions of interest (e.g., CDKN2A) are initially 
amplified by multiplex PCR. Individual probes with the interrogative terminal codon are linked to a unique 24-mer Tag sequence and subjected to allele-
specific primer extension (ASPE). The ASPE extension step uses biotinylated deoxycytidine triphosphates, thereby introducing a biotin-labeled moiety into 
the extended fragment. The 24-mer Tag/biotinylated ASPE fragment is then specifically captured by a color-coded bead adorned with an anti-Tag, which fully 
complements the 24-mer Tag sequence. Streptavidin-conjugated phycoerythrin (SA-PE) is then introduced to detect an intensity signal. In summary, the bead 
color defines the address—i.e., the individual single-nucleotide polymorphism (SNP)—and the PE fluorescence intensity defines the amount of the specific SNP 
fragment. Reprinted with permission from Lang et al. (2011).
including protein expression profiling, gene expression 
profiling, molecular basis of infectious disease, and HLA testing. 
In recent years, multiplex PCR and Luminex technology have 
been used to identify high-risk mutations in cyclin-dependent 
kinase inhibitor 2A/cyclin-dependent kinase 4 (CDKN2A/
CDK4) among genomic DNA from melanoma-prone families 
(Figure 2) (Lang et al., 2011). The Luminex assay quickly and 
accurately genotyped CDKN2A/CDK4 mutations in a large 
number of samples, demonstrating its utility as a sensitive, cost-
effective, and reliable method for the screening of mutations 
associated with an increased risk of melanoma. The ability to 
analyze a variety of biological samples including tissue and cell 
lysate, saliva, sputum, serum, plasma, and urine adds to the ver-
satility of the Luminex platform as a useful screening modality. 
COMPARISON WITH ELISA AND MICROARRAY  
FOR CYTOKINE PROFILING
Luminex has several distinct advantages over similar bioas-
says, such as ELISA and microarray. Conceptually, the analy-
sis of each microsphere is essentially an ELISA on a bead 
(Dupont et al., 2005). This enables multiplexing of up to 100 
different analytes in a single well of a Luminex assay because 
each microsphere serves as an individual test, thereby pro-
viding higher throughput than ELISA. The three-dimensional 
structure and small surface area of the microspheres allow for 
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faster reaction kinetics and shorter assay times than ELISAs 
and microarrays, which are limited by solid-phase kinetics. 
Luminex assays also offer the flexibility to customize and 
attach specific probes to uniquely colored microspheres, 
easily expanding and readily adapting to specific muta-
tions in specific populations as they are identified, which 
has important implications for its use as a screening tool. 
Notably, Luminex requires small sample volumes of only 50 
μl per well, greatly diminishing the sample volume required 
compared to ELISA. Thus, more data are generated from the 
same sample volume. 
Luminex is unique in that it offers both high-density 
(multiplexing 100 tests per sample) and high-throughput 
(can test up to 1,000 samples per day) simultaneously, 
with results that are highly reproducible, reliable, and as 
accurate as an ELISA. Although ELISA and real-time PCR 
have the capacity for high throughput (i.e., it is possible to 
analyze hundreds of samples per day), they are unable to 
multiplex more than a few tests at a time. Microarrays, on 
the other hand, provide high-density screening of several 
hundred tests at a time, but are limited by their lack of 
reproducibility needed for high-throughput analyses. 
However, several factors may limit the utility and 
availability of Luminex. First, the Luminex platform requires 
dedicated analysis instruments that are similar to flow 
cytometers, which therefore increases the upfront costs 
associated with this system. Development of newer light-
emitting diode–based systems, as opposed to laser-based 
units, will likely significantly decrease the initial cost to 
utilize this assay. Luminex assays are also subject to vari-
ability because of assay manufacturer, product lot number, 
and assay execution (Lynch et al., 2014); however, using the 
same manufacturer in a given assay and maintaining con-
sistent methodology can minimize variability. Additionally, 
the presence of human autoantibodies in some biologi-
cal samples may confound the measurement of cyto-
kines in clinical assays as a result of nonspecific binding. 
Fortunately, several methods are available to remove these 
autoantibodies while maintaining the integrity of the resul-
tant cytokine profile (de Jager et al., 2005).
CONCLUSION
Luminex is an important tool in the interrogation of the 
cytokine milieu in physiologic and pathologic processes 
because it enables patterns of cytokines to be evaluated, 
thereby providing a more comprehensive depiction of the 
complex cell signaling network than was previously pos-
sible. It provides more robust data delivery with higher 
throughput and density than traditional methods, but with 
accuracy comparable to that of ELISA. Luminex requires 
significantly lower sample volumes and shorter assay times 
than ELISA, and it can be utilized for a variety of applica-
tions beyond cytokine profiling, including protein and gene 
expression profiling, biomarker identification, and drug 
discovery. New light-emitting diode–based Luminex instru-
ments offer the promise of reduced installation costs and, 
therefore, increased availability to potential users. 
1.  How many distinct cytokines or analytes can be interrogated in 






2.  What type(s) of biological sample(s) can be analyzed using 
Luminex?
 A. Tissue and cell lysate.
 B.  Saliva.
 C.  Sputum.
 D.  Serum.
 E.  Plasma.
 F.  Urine.
 G.  All of the above.
3.  Which of the following is not true regarding the Luminex plat-
form versus other comparable bioassays?
 A.  It has the capacity for high-throughput and high-density 
data delivery with excellent accuracy compared to alterna-
tive methods. 
 B.  Luminex requires the use of dedicated analysis instruments 
similar to flow cytometers.
 C.  Luminex and ELISA require similar sample volumes for 
analysis.
 D.  The three-dimensional structure and small surface area of 
Luminex microspheres accelerates the reaction kinetics and 
decreases total assay time.
4.  Which of the following compounds can be conjugated to the 
surface of the Luminex microsphere?
 A. Antibodies.
 B.  Receptors.
 C. Peptides.
 D.  Oligonucleotides.
 E.  All of the above.
 F.  None of the above.
5.  How does the Luminex system differentiate among various 
cytokines?
 A.  A reporter dye is conjugated to a detection antibody that 
is subsequently excited by the green laser of the Luminex 
system.
 B.  Each microsphere set is internally dyed with a graded mix-
ture of red and infrared fluorescent dyes, and excitation of 
the bead by the red laser emits a fluorescent signature that 
is unique to each cytokine.
 C.  Only one cytokine can be tested per well and the user must 
decide which cytokine to test for in advance and input this 
information into the analysis software.
 D.  The fluorescent signal emitted from the internally dyed 
microsphere and the externally conjugated detection anti-
body are combined to identify the particular cytokine of 
interest.
QUESTIONS
This article has been approved for 1 hour of Category 1 CME credit.  
To take the quiz, with or without CME credit, follow the link under  
the “CME ACCREDITATION” heading.
For each question, more than one answer may be correct.
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A PowerPoint slide presentation appropriate for journal club or other teaching 
exercises is available at http://dx.doi.org/10.1038/jid.2015.36.
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